Research programme: controlled-release therapeutics - Camurus/undiclosed companies

Drug Profile

Research programme: controlled-release therapeutics - Camurus/undiclosed companies

Latest Information Update: 04 May 2016

Price : $50

At a glance

  • Originator Camurus; Unknown
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Endocrine disorders; Metabolic disorders; Pain; Viral infections

Most Recent Events

  • 31 Dec 2015 Preclinical trials in Viral infections in Sweden (unspecified route) before December 2015
  • 31 Dec 2015 Preclinical trials in Endocrine disorders in Sweden (unspecified route) before December 2015
  • 01 Jan 2014 Preclinical trials in Pain in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top